Insider · CIK 0001184847
Douglas E Williams
director
Files at CAMP (Camp4 Therapeutics Corp), CLYM (Climb Bio, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | CLYM Climb Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 5, 2025 |
| Mar 31, 2025 | CLYM Climb Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +78,873 | $0.00 | $0 | 78,873 | Apr 1, 2025 |
| Mar 17, 2025 | CAMP Camp4 Therapeutics Corp | AGrant or award Stock Option (Right to Buy)derivative | +17,787 | $0.00 | $0 | 17,787 | Mar 19, 2025 |
| Nov 11, 2024 | CLYM Climb Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Nov 12, 2024 |
| Nov 11, 2024 | CLYM Climb Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,291 | $0.00 | $0 | 6,291 | Nov 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.